Instructions for use

Clinical features of isolated gestational proteinuria progressing to pre-eclampsia: retrospective observational study

Author(s)
Akaishi, Rina; Yamada, Takahiro; Morikawa, Mamoru; Nishida, Ryutaro; Minakami, Hisanori

Citation
BMJ Open, 4(4), e004870
https://doi.org/10.1136/bmjopen-2014-004870

Issue Date
2014-04-19

Doc URL
http://hdl.handle.net/2115/56535

Rights(URL)
http://creativecommons.org/licenses/by-nc/3.0/

Type
article

File Information
BMJ Open_4(4)_e004870.pdf
Clinical features of isolated gestational proteinuria progressing to pre-eclampsia: retrospective observational study

Rina Akaishi, Takahiro Yamada, Mamoru Morikawa, Ryutaro Nishida, Hisanori Minakami

ABSTRACT

Objectives: Some women with isolated gestational proteinuria (IGP) later develop hypertension and are diagnosed with pre-eclampsia (PE). This study was performed to determine whether clinical features of such proteinuria preceding PE (P-PE) differ from those of other PE (O-PE).

Design: Retrospective observational study after approval of the institutional review board of ethics.

Setting: A single university hospital. Proteinuria was defined as a protein-to-creatinine ratio (mg/mg; P/Cr) of ≥0.27 in the spot urine specimen. IGP was defined as proteinuria in the absence of hypertension. P-PE was defined as PE in which proteinuria preceded hypertension by more than 2 days.

Participants: All of 10 and 18 consecutive women with P-PE and O-PE, respectively, who gave birth between January 2008 and August 2013.

Results: Proteinuria appeared earlier (at 30.2±3.0 vs 35.3±4.3 weeks, p=0.001), the P/Cr level was greater at birth (7.28±2.14 vs 3.19±2.49, p<0.001), net maternal weight gain during the last antenatal 1 week was greater (3.1±1.8 vs 1.3±1.7 kg, p=0.023) and length of pregnancy was shorter (32.5±1.9 vs 36.1±3.6 weeks, p=0.001) in women with P-PE than in O-PE. The duration of IGP was 10.0±5.9 days (range 3–20), and the time interval until delivery after diagnosis of PE was 6.1±8.2 days (range 0–23) in 10 women with P-PE. The P/Cr levels at birth were significantly inversely correlated with the antenatal lowest antithrombin activity and fibrinogen levels among the 28 women with PE.

Conclusions: Women with P-PE were likely to exhibit greater proteinuria in the urine, greater water retention in the interstitial space and more enhanced coagulation–fibrinolysis, thus suggesting that they may constitute a more severe form of PE than women with O-PE do.

INTRODUCTION

Pre-eclampsia (PE) remains a leading cause of maternal and perinatal mortality and morbidity. Hypertensive disorders are responsible for approximately one quarter of all maternal deaths in Latin America and the Caribbean. Hypertensive disorders encoded O-10 to O-16 by ICD-10 accounted for 8.1% and 4.4% of all maternal mortalities in Japan in 2005 and 2010, respectively.

The current criteria for diagnosis of PE are systolic blood pressure (SBP) ≥140 mm Hg or diastolic blood pressure (DBP) ≥90 mm Hg with proteinuria of ≥0.3 g/day. Thus, assessment of proteinuria is an important constituent of antenatal care to detect women with PE. Although proteinuria has
been considered as a late sign of the clinical course of PE. It was recently demonstrated that some women exhibit proteinuria first in the absence of hypertension, so-called ‘isolated gestational proteinuria (IGP)’, and develop hypertension later and are diagnosed as having PE. The IGP was proposed to be an early clinical sign of PE. As approximately 15–26% of women with new onset of hypertension alone in pregnancy develop proteinuria later and are diagnosed as having PE; there are two types of women with PE: those who develop proteinuria first significantly earlier than hypertension, and those who develop hypertension first or hypertension and proteinuria simultaneously.

Frequent laboratory workup, at least twice in a week, is recommended in women with PE. However, there have been no extensive studies regarding whether clinical and laboratory features of such women with proteinuria preceding PE (P-PE) differ from those of other women with PE.

METHODS
This study was conducted with the approval of the Institutional Review Board of Hokkaido University Hospital, a tertiary teaching hospital managing mainly high-risk pregnant women. Laboratory tests, including complete blood count, biochemistry and parameters of coagulation–fibrinolysis, such as antithrombin activity, are performed routinely in pregnant women visiting our clinic even for minor symptoms as well as those admitted to the hospital for management of various obstetric and incidental complications.

DEFINITION OF TERMS USED IN THIS STUDY AND STUDY PROTOCOL
Pregnant Japanese women receive 14–15 antenatal care visits before delivery and undergo determination of blood pressure, proteinuria by dipstick testing and body weight at each visit. A spot urine specimen with a net weight gain exceeding P/Cr (mg/mg) of 5.0 in the spot urine; liver dysfunction evidenced by an elevated aspartate aminotransferase (>45 IU/L) level concomitant with a reduced platelet count (<120×10^9/L) and/or a reduced antithrombin activity level (<65% of normal activity level); and a net weight gain ≥5 kg/week.

INDICATION FOR AN EARLY DELIVERY IN WOMEN WITH PE
Induced labour or caesarean section were indicated in women with PE with one or more of the following: uncontrollable hypertension exceeding SBP ≥180 mm Hg and/or DBP ≥110 mm Hg even with antihypertensive agents; gradual increase in proteinuria exceeding P/Cr (mg/mg) ≥5.0 in the spot urine; liver dysfunction evidenced by an elevated aspartate aminotransferase (>45 IU/L) level concomitant with a reduced platelet count (<120×10^9/L) and/or a reduced antithrombin activity level (<65% of normal activity level); and a net weight gain ≥5 kg/week.

STATISTICAL ANALYSES
Data are presented as means±SD. Statistical analyses were performed using the JMP10 statistical software package (SAS, Cary, North Carolina, USA). Differences between the means were tested by analysis of variance and Tukey-Kramer HSD (honestly significant difference) test between each group, and categorical variables were compared using the χ^2 test or Fisher’s exact probability test. In all analyses, p<0.05 was taken to indicate statistical significance.
RESULTS
Of the 28 women with PE, 10 (36%) had a duration of IGP ≥ 3 days, and therefore had P-PE, and the remaining 18 women (64%) exhibited no IGP or had a duration of IGP < 3 days, and therefore had O-PE (table 1). Of the 18 women with O-PE, the duration of GH was 3 days or more in 8 women (H-PE group). There were no significant differences in clinical background between women with H-PE and S-PE (in whom the duration of IGP or GH was ≤ 2 days; table 1). Women with P-PE were significantly more likely to develop proteinuria and hypertension earlier and gave birth earlier compared to those with O-PE.

The P/Cr levels increased with advancing gestation in P-PE and O-PE groups (figure 1). The P/Cr level at birth was significantly higher in women with P-PE than in O-PE. The antenatal duration of proteinuria in women with P-PE, 16.1±10.3 days, did not differ from the antenatal duration of hypertension of 10.9±9.8 days in women with O-PE. The time interval until delivery after diagnosis of PE did not differ between the two groups (6.1±8.2 days for P-PE vs 5.9±6.8 days for O-PE; figure 1). Proteinuria disappeared in 4 (40%) of the 10 women with P-PE and 13 (72%) of the 18 women with O-PE at 1-month postpartum and in 7 (70%) and 18 (100%), respectively, at 2 months postpartum. Three women with P-PE and proteinuria at 2 months postpartum exhibited no proteinuria at 3 months postpartum.

Net maternal weight gain in pregnancy did not differ between the P-PE and O-PE groups, although the gestation period was significantly shorter in women with P-PE than in O-PE (table 1). This may have reflected a significantly greater net maternal weight gain during the last antenatal 1 week in women with P-PE compared with O-PE (figure 2). Net maternal weight gains for the last 1 week (3.1±1.8 vs 1.3±1.7 kg, p=0.023) and for the last 3 days (2.2±1.4 vs 0.5±1.4 kg, p=0.005) were significantly greater in women with P-PE than in those with O-PE.

Although most blood test results did not differ significantly between women with P-PE and O-PE, creatinine level was significantly higher and antithrombin activity and fibrinogen level tended to be lower in women with P-PE than in those with O-PE (table 2), suggesting that these parameters were associated with P/Cr levels. Indeed, the highest antenatal P/Cr levels were significantly inversely correlated with the lowest antenatal antithrombin activity and fibrinogen levels, but not with the lowest antenatal platelet counts or the highest antenatal levels of uric acid and creatinine (figure 3).

DISCUSSION
In this study, 36% of all the 28 women with PE during the study period developed proteinuria first and hypertension later, confirming that a considerable number of women with PE develop proteinuria first and subsequently develop hypertension. This phenomenon was first described in the literature in 2008\(^5\) followed by reports that the appearance of IGP as determined by dipstick test is associated with established risk factors for PE, such as higher pre-pregnancy body mass index, nulliparity, twin pregnancy and elevation of blood pressure in late pregnancy,\(^8\) supporting the hypothesis that IGP is

---

Table 1 Demographic characteristics of two (three) groups

<table>
<thead>
<tr>
<th></th>
<th>Other types of PE</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>P-PE</td>
<td>O-PE</td>
<td>H-PE</td>
<td>S-PE</td>
</tr>
<tr>
<td>Number of women</td>
<td>10</td>
<td>18</td>
<td>8</td>
<td>10</td>
</tr>
<tr>
<td>Age (year)</td>
<td>35.5±3.1</td>
<td>34.2±5.2</td>
<td>34.8±4.7</td>
<td>33.7±5.8</td>
</tr>
<tr>
<td>Nulliparous</td>
<td>5 (50%)</td>
<td>11 (61%)</td>
<td>4 (50%)</td>
<td>7 (70%)</td>
</tr>
<tr>
<td>Twin pregnancy</td>
<td>0 (0.0%)</td>
<td>5 (28%)</td>
<td>3 (38%)</td>
<td>2 (20%)</td>
</tr>
<tr>
<td>Pre-pregnancy BMI</td>
<td>19.5±2.9</td>
<td>21.2±3.5</td>
<td>21.3±3.0</td>
<td>21.1±4.0</td>
</tr>
<tr>
<td>Body weight at delivery (kg)</td>
<td>61.6±8.9</td>
<td>66.1±7.1</td>
<td>67.1±8.2</td>
<td>65.4±6.6</td>
</tr>
<tr>
<td>Net weight gain in pregnancy (kg)</td>
<td>12.2±2.9</td>
<td>13.6±5.5</td>
<td>14.5±5.1</td>
<td>12.9±6.0</td>
</tr>
<tr>
<td>Caesarean delivery</td>
<td>10 (100%)</td>
<td>14 (78%)</td>
<td>6 (75%)</td>
<td>8 (80%)</td>
</tr>
<tr>
<td>Systolic blood pressure (mm Hg)</td>
<td>164±10</td>
<td>173±14</td>
<td>173±18</td>
<td>172±12</td>
</tr>
<tr>
<td>Diastolic blood pressure (mm Hg)</td>
<td>96±7.2</td>
<td>97±13</td>
<td>95±13</td>
<td>98±13</td>
</tr>
<tr>
<td>Gestational week at</td>
<td>Proteinuria†</td>
<td>30.2±3.0</td>
<td>35.3±4.3*</td>
<td>34.4±4.1*</td>
</tr>
<tr>
<td></td>
<td>Hypertension</td>
<td>31.6±2.7</td>
<td>34.6±4.4*</td>
<td>32.9±3.8</td>
</tr>
<tr>
<td></td>
<td>Delivery</td>
<td>32.5±1.9</td>
<td>36.1±3.6*</td>
<td>35.5±3.6</td>
</tr>
<tr>
<td></td>
<td>&lt;37</td>
<td>10 (100%)</td>
<td>10 (56%)*</td>
<td>6 (75%)</td>
</tr>
<tr>
<td>Birth weight (g)</td>
<td>1445±597</td>
<td>2219±692*</td>
<td>2150±546*</td>
<td>2281±823*</td>
</tr>
<tr>
<td></td>
<td>&lt;2500</td>
<td>10 (100%)</td>
<td>14 (78%)</td>
<td>7 (88%)</td>
</tr>
</tbody>
</table>

Data are presented as means±SD.
† Defined as a protein-to-creatinine ratio ≥ 0.27 in the spot urine.
BMI, body mass index; H-PE, hypertension preceding pre-eclampsia; O-PE, other pre-eclampsia including H-PE and S-PE; P-PE, proteinuria preceding pre-eclampsia; S-PE, simultaneous pre-eclampsia.
part of the disease spectrum of PE. In addition, women with IGP defined by repeated positive dipstick test results in two successive antenatal visits show increased likelihood of developing PE.12

The P/Cr levels have been validated as a proxy for 24 h collection in non-pregnant patients, and determination of P/Cr is the preferred method for evaluation of the amount of protein loss in the urine outside of obstetrics.13 A P/Cr level around 0.27 is a reasonable cut-off level to exclude or detect proteinuria of 0.3 g/day,14 although the prognostic value of different quantities of urinary protein is unclear and further studies to identify diagnostic thresholds of proteinuria that are accurate for predicting clinically important outcomes is needed.10 A recent study examining the occurrence of adverse maternal and perinatal outcomes with different thresholds of proteinuria (0.3–0.49 and ≥0.5 g/day, respectively) in women with PE confirmed that 0.3 g/day is an appropriate threshold.15 It may be clinically beneficial to be aware of physiological changes in the amount of protein loss in the urine of pregnant women. Among otherwise healthy women who do not develop PE, mean P/Cr level increases with advancing gestation in singleton and twin pregnancies, and women with twins are significantly more likely to have high P/Cr level than those with singleton pregnancies16: the mean P/Cr of 0.06 and 0.10 for singletons and twins, respectively, at GW 16–20 increased to 0.09 and 0.12 at GW 20–28 and to 0.15 and 0.22 at GW 34–38, respectively. In the 10 women with P-PE in this study, the mean P/Cr level continued to increase until delivery after showing P/Cr ≥0.27 (figure 1). These results suggested that the P/Cr increases linearly in some pregnant women in whom it exceeds a cut-off level of 0.27 in the absence of hypertension.

As mentioned above, P/Cr increases with advancing gestation. The P/Cr at birth was significantly greater in women with P-PE than in O-PE, perhaps reflecting the significantly longer antenatal duration of proteinuria in the former than in the latter group (figure 1). However, the time interval after onset of proteinuria until delivery in women with P-PE did not differ from that after onset of hypertension until delivery in women with P-PE (16.1 ±10.3 vs 10.9±9.8 days, respectively). In addition, the time intervals after diagnosis of PE until delivery were similar in both groups (6.1±8.2 vs 5.9±6.8 days, respectively). These observations suggested that IGP should be considered as an important clinical sign equal to hypertension.

In the present study, women with P-PE showed significantly greater maternal weight gain in the last antenatal 1 week compared to those with O-PE. The net weight gains of 4.2 and 3.1 kg in the last 2 weeks and 1 week in women with P-PE accounted for approximately 34% and 25% of the total weight gain of 12.2 kg in pregnancy, respectively, while respective values of 1.6 and 1.3 kg in women with O-PE accounted for 12% and 9.6% of the total weight gain of 13.6 kg. As the mean±SD weekly

**Figure 1** Changes in degree of proteinuria in relation to the timing of hypertension onset in the two groups. Open and closed circles indicate women with P-PE (n=10) and O-PE (n=18), respectively. *p<0.001 for differences between two levels. In women with P-PE, the P/Cr levels were 1.45±1.16, 5.63±2.27 and 7.28±2.14 when diagnosed with IGP, PE and on giving birth, respectively. In women with O-PE, the P/Cr levels were 1.70±1.81 and 3.19±2.49 when diagnosed with PE and on giving birth, respectively. The duration of IGP was 10.0±5.9 days (range 3–20) and the time interval until delivery after diagnosis of PE was 6.1±8.2 days (range 0–23) in women with P-PE. The duration of GH was 4.9±6.5 days (range 0–20) and the time interval until delivery after diagnosis of PE was 5.9±6.8 days (range 0–22) in women with O-PE. GH, gestational hypertension; IGP, isolated gestational proteinuria; O-PE, other pre-eclampsia; P-PE, proteinuria preceding pre-eclampsia; P/Cr, protein-to-creatinine ratio.

**Figure 2** Net perinatal changes in maternal body weight. Open and closed circles indicate women with P-PE and O-PE, respectively. *p<0.05 versus women with O-PE. When data on body weight for the designated days were not available, data on the day before or after the designated days were used. Net antenatal maternal weight gain was 4.2±1.7 vs 1.6±2.8 kg (p=0.074) for the last antenatal 2 weeks, 3.1 ±1.8 vs 1.3±1.7 kg (p=0.023) for the last antenatal 1 week and 2.2±1.4 vs 0.5±1.4 kg (p=0.005) for the last antenatal 3 days in women with P-PE versus O-PE, respectively. Corrected weight loss during 4 weeks postpartum (maternal body weight just before delivery minus the sum of infant birth weight and maternal body weight at 4 weeks postpartum) was 9.4±2.0 vs 7.3±3.8 kg (p=0.109) in women with P-PE versus O-PE, respectively. O-PE, other pre-eclampsia; P-PE, proteinuria preceding pre-eclampsia.
Table 2  Lowest/highest antenatal levels of blood variables in two (three) groups

<table>
<thead>
<tr>
<th>Other types of PE</th>
<th>Overall</th>
<th>H-PE</th>
<th>S-PE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of women</td>
<td>18</td>
<td>8</td>
<td>10</td>
</tr>
<tr>
<td>Platelet (×10^9/L)</td>
<td>159±49</td>
<td>159±46</td>
<td>158±50</td>
</tr>
<tr>
<td>&lt;120</td>
<td>5 (27.8%)</td>
<td>2 (25%)</td>
<td>3 (30%)</td>
</tr>
<tr>
<td>Antithrombin activity</td>
<td>73.8±10.1</td>
<td>71.4±8.0</td>
<td>75.7±11.6</td>
</tr>
<tr>
<td>&lt;65%</td>
<td>4 (22.2%)</td>
<td>2 (25%)</td>
<td>2 (20%)</td>
</tr>
<tr>
<td>AST (IU/L)</td>
<td>27.2±11.6</td>
<td>28.4±10.3</td>
<td>26.2±13.0</td>
</tr>
<tr>
<td>&gt;45%</td>
<td>3 (16.7%)</td>
<td>1 (12.5%)</td>
<td>2 (20%)</td>
</tr>
<tr>
<td>LDH (IU/L)</td>
<td>255±47</td>
<td>268±49</td>
<td>244±48</td>
</tr>
<tr>
<td>&gt;400%</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Uric acid (mg/dL)</td>
<td>6.1±1.1</td>
<td>6.3±0.8</td>
<td>6.0±1.3</td>
</tr>
<tr>
<td>&gt;6.0%</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>LDH (mg/dL)</td>
<td>334±98</td>
<td>295±83</td>
<td>365±102*</td>
</tr>
<tr>
<td>&lt;300%</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Creatinine (mg/dL)</td>
<td>0.57±0.10*</td>
<td>0.61±0.12</td>
<td>0.53±0.04*</td>
</tr>
<tr>
<td>&gt;0.7%</td>
<td>2 (11.1%)</td>
<td>2 (25%)</td>
<td>0 (0%)</td>
</tr>
</tbody>
</table>

Reference interval (not specific for pregnant women) was 80–130% for antithrombin activity.

*p<0.05 vs P-PE.

AST, aspartate aminotransferase; H-PE, hypertension preceding pre-eclampsia; LDH, lactate dehydrogenase; P-PE, proteinuria preceding pre-eclampsia; S-PE, simultaneous pre-eclampsia.

![Figure 3](https://example.com/figure3.png)

Figure 3  Correlation between degree of antenatal proteinuria and antenatal blood variables. Open and closed circles indicate women with P-PE and O-PE, respectively. The highest antenatal P/Cr levels were significantly inversely correlated with either the lowest antenatal antithrombin activity levels or the lowest antenatal fibrinogen levels, but not with the lowest antenatal platelet counts, the highest antenatal uric acid levels or the highest antenatal creatinine levels. O-PE, other pre-eclampsia; P/Cr, protein-to-creatinine ratio; P-PE, proteinuria preceding pre-eclampsia.
weight gain, defined as (maternal weight at delivery – pre-pregnancy maternal weight)/(GW at delivery – 2), is 0.26±0.12 kg for Japanese women with singleton pregnancies not complicated with pregnancy-induced hypertension, and weight gain in the last antenatal 2 weeks is 0.9±0.9 kg for otherwise healthy Japanese women with singleton pregnancies; these results indicated that although oedema due to the accumulation of excess water in the interstitial space occurred in late pregnancy in P-PE and O-PE, its degree was greater in women with P-PE than in those with O-PE.

Excessive weight gain during the final stage of pregnancy is suggested to be a risk factor for eclampsia. The daily protein loss in the urine was greater in women with P-PE than in those with O-PE, and the degree of proteinuria was inversely correlated with reductions of antithrombin activity and fibrinogen level in this study. A decrease in antithrombin activity has also been suggested to be a risk factor for eclampsia. As enhanced coagulation–fibrinolysis is a characteristic laboratory finding in women with PE, the degree of reduction in fibrinogen level may reflect the severity of PE. The circulating plasma volume was reduced in women with PE, and serum creatinine level was significantly higher in women with P-PE than in those with O-PE in the present study, suggesting a greater decrease in circulating plasma volume in women with P-PE. Taken together, these results suggest that P-PE constitutes a more serious condition than other types of PE.

STUDY LIMITATIONS
IGP developed at GW 30.0±3.0, while GH developed at GW 32.9±3.8 in this study (table 1), suggesting that IGP occurs earlier than GH. However, this may not be a general characteristic and may have been distorted by incidental bias due to the small size of the study population. Although the definition of proteinuria differed between the present study and our previous study, IGP occurred at a mean GW of 31.1 in 19 women with IGP preceding PE, while GH occurred at mean GW of 28.2 in 5 women with GH preceding PE in the previous study. In another study to determine the fraction of women who developed PE among those with GH, GH developed at GW 33±4 in 26 women with GH preceding PE. As IGP and GH may occur at any time point on or after GW 20, and as there have been no reports regarding the number of women who develop GH and IGP according to GW, the mean GW at the onset of IGP and GH in the present study and previous reports may have been subject to incidental bias due to the limited number of study patients.

CONCLUSIONS
We compared the clinical features of 10 consecutive women who first developed IGP and later developed hypertension with those of 18 consecutive women who developed hypertension first or hypertension and proteinuria simultaneously and were diagnosed with PE. The P/Cr level at birth and net maternal weight gain in the last antenatal 1 week were greater in the former than the latter group. The P/Cr levels at birth were significantly inversely correlated with the lowest antenatal antithrombin activities and fibrinogen levels among women with PE. All of these results suggested that women with PE along with IGP followed by hypertension constitute a more severe PE group.

Contributors RA was involved in drafting the manuscript, data collection and analysis. TY was involved in study design, data collection and analysis. MM was involved in study design and data collection. RN was involved in data collection. HM was involved in study design and supervision of this study.

Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None.

Ethics approval The Institutional Review Board of Hokkaido University Hospital.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

REFERENCES


